These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 37489368)

  • 1. Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy.
    Chung C; Kudchodkar SB; Chung CN; Park YK; Xu Z; Pardi N; Abdel-Mohsen M; Muthumani K
    Antibodies (Basel); 2023 Jul; 12(3):. PubMed ID: 37489368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery.
    Kaliyaperumal R; Ranganathan S; Krishnamoorthy M; Mohan VK; Balaraman S; Rajapandian G; Sathiyasundar R; Ravindran S
    Recent Adv Drug Deliv Formul; 2023; 17(4):264-285. PubMed ID: 37909435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ production of therapeutic monoclonal antibodies.
    Suscovich TJ; Alter G
    Expert Rev Vaccines; 2015 Feb; 14(2):205-19. PubMed ID: 25578347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage
    Duperret EK; Trautz A; Stoltz R; Patel A; Wise MC; Perales-Puchalt A; Smith T; Broderick KE; Masteller E; Kim JJ; Humeau L; Muthumani K; Weiner DB
    Cancer Res; 2018 Nov; 78(22):6363-6370. PubMed ID: 30287678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy.
    Baker A; Lorch J; VanderWeele D; Zhang B
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.
    Muthumani K; Flingai S; Wise M; Tingey C; Ugen KE; Weiner DB
    Hum Vaccin Immunother; 2013 Oct; 9(10):2253-62. PubMed ID: 24045230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-based genetic immunotherapy.
    Pelegrin M; Gros L; Dreja H; Piechaczyk M
    Curr Gene Ther; 2004 Sep; 4(3):347-56. PubMed ID: 15384948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies - SARS CoV-2 as an example.
    El Abd Y; Tabll A; Smolic R; Smolic M
    Hum Antibodies; 2022; 30(1):15-24. PubMed ID: 34958012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New application of anti-TLR monoclonal antibodies: detection, inhibition and protection.
    Fukui R; Murakami Y; Miyake K
    Inflamm Regen; 2018; 38():11. PubMed ID: 29988708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies.
    Patel A; Bah MA; Weiner DB
    BioDrugs; 2020 Jun; 34(3):273-293. PubMed ID: 32157600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
    Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
    Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopharmaceuticals and monoclonal antibodies in oncology trials--a cross-sectional analysis.
    Janowitz T
    Protein Eng Des Sel; 2011 Jan; 24(1-2):105-11. PubMed ID: 21037277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in monoclonal antibody-based therapies.
    Samaranayake H; Wirth T; Schenkwein D; Räty JK; Ylä-Herttuala S
    Ann Med; 2009; 41(5):322-31. PubMed ID: 19234897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for cancer treatment.
    Donátová K; Nováková E; Šupolíková M
    Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in novel delivery technologies to improve efficacy of therapeutic antibodies.
    Sun W; Wu Y; Ying T
    Antiviral Res; 2024 May; 225():105867. PubMed ID: 38521465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplifying checkpoint inhibitor delivery through
    Perales-Puchalt A; Duperret EK; Muthumani K; Weiner DB
    Oncotarget; 2019 Jan; 10(1):13-16. PubMed ID: 30713599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic organoids: a new approach to cancer treatment.
    Compte M; Nuñez-Prado N; Sanz L; Alvarez-Vallina L
    Biomatter; 2013; 3(1):. PubMed ID: 23507921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies.
    Singh Gautam A; Pandey SK; Lasure V; Dubey S; Singh RK
    Expert Opin Biol Ther; 2023; 23(7):603-618. PubMed ID: 37334564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies as diagnostics; an appraisal.
    Siddiqui MZ
    Indian J Pharm Sci; 2010 Jan; 72(1):12-7. PubMed ID: 20582184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.